

Remarks

As directed by the Notice to Comply, this amendment directs the Office to enter the attached copy of the Sequence Listing into the Specification. The new Sequence Listing was amended to replace the term “artificial” as cited in the Sequence Listing in Section <213> with the phrase “artificial sequence.” The content of such Sequence Listing in computer readable form does not include matter which goes beyond the disclosure of the U.S. Application as originally filed. Therefore, applicants assert that the present submission includes no new matter.

Respectfully submitted,

/Robert L. Sharp/
Robert L. Sharp
Attorney for Applicants
Registration No. 45,609
Phone: 317-651-1541

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

January 11, 2010